{"@context":"https:\/\/schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"A Phase 2, Randomized, Double-Blind, Placebo- and Active-Comparator Controlled Clinical Study of V940 (mRNA-4157) Plus Pembrolizumab Versus Placebo Plus Pembrolizumab in Participants With First-Line Advanced Melanoma (INTerpath-012)","item":"https:\/\/www.regionalcancercare.org\/trials\/a-phase-2-randomized-double-blind-placebo-and-active-comparator-controlled-clinical-study-of-v940-mrna-4157-plus-pembrolizumab-versus-placebo-plus-pembrolizumab-in-participants-with-first-line-a\/#breadcrumbitem"}]}